Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Alexander disease type II (AxD type II) is an astrogliopathy and a form of Alexander disease (AxD) characterized by ataxia, bulbar symptoms, spastic paraparesis, palatal myoclonus, and autonomic symptoms.
Biomarker and diagnostic research for Alexander disease type II has been reported in the published literature.
Estimated prevalence: Unknown (Unknown prevalence).
No clinical trials have been registered for Alexander disease type II.
57 publications have been identified in PubMed for Alexander disease type II. Research spans Clinical Trial Publication (38%), Basic Science / Preclinical (28%), and Review / Meta-Analysis (13%).
Research Type | Count | % of Total |
|---|---|---|
Clinical study results | 20 | 38% |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 6:21 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Alexander disease type II
15 |
28% |
Research summaries | 7 | 13% |
Patient case studies | 4 | 8% |
Disease patterns and progression | 3 | 6% |
Testing and diagnosis research | 2 | 4% |
Other research | 1 | 2% |
New treatment approaches | 1 | 2% |
Elsayed NA (2026). [PMID: 41827061](https://pubmed.ncbi.nlm.nih.gov/41827061/). *Acta Neuropathol Commun*. [Basic Science / Preclinical]
Bachetti T (2026). [PMID: 41349291](https://pubmed.ncbi.nlm.nih.gov/41349291/). *Mol Genet Metab*. [Basic Science / Preclinical]
Burgard LC (2026). [PMID: 41829937](https://pubmed.ncbi.nlm.nih.gov/41829937/). *Nutrients*. [Diagnostic / Biomarker]
Solberg T (2026). [PMID: 41101608](https://pubmed.ncbi.nlm.nih.gov/41101608/). *Fish Shellfish Immunol*. [Clinical Trial Publication]
Hinkson A (2026). [PMID: 42086293](https://pubmed.ncbi.nlm.nih.gov/42086293/). *BMJ Open Gastroenterol*. [Basic Science / Preclinical]
Chinnathambi S (2026). [PMID: 41904009](https://pubmed.ncbi.nlm.nih.gov/41904009/). *Adv Protein Chem Struct Biol*. [Review / Meta-Analysis]
Garantziotis P (2026). [PMID: 40701862](https://pubmed.ncbi.nlm.nih.gov/40701862/). *Ann Rheum Dis*. [Basic Science / Preclinical]
Haas D (2026). [PMID: 41849874](https://pubmed.ncbi.nlm.nih.gov/41849874/). *JACC Adv*. [Epidemiology / Natural History]
Kunkyab T (2026). [PMID: 41775003](https://pubmed.ncbi.nlm.nih.gov/41775003/). *Clin Oncol (R Coll Radiol)*. [Clinical Trial Publication]
Ostendorf L (2026). [PMID: 41629292](https://pubmed.ncbi.nlm.nih.gov/41629292/). *Nat Commun*. [Clinical Trial Publication]
AI-curated news mentioning Alexander disease type II
Updated Sep 9, 2026
Ionis Pharmaceuticals secures the first targeted approval for Alexander disease, marking a significant milestone in rare disease treatment. Meanwhile, Novo Nordisk and Novartis face setbacks with late-stage trial cancellations and Phase 3 failures in cardiovascular and muscular dystrophy indications.
New research explores cellular models for studying Alexander disease through the functional analysis of primary rat astrocytes. This study contributes to understanding the disease mechanisms and potential therapeutic targets.
FDA approves Zanvastro for Alexander disease, marking a significant milestone as the first approved treatment for this rare neurological condition. This approval highlights the ongoing advancements in rare disease therapies.
A recent study highlights cognitive impairment as a significant issue in adults with Alexander disease. This research adds to the understanding of the disease's impact on cognitive functions.
A recent study highlights the clinical and radiological variability of adult-onset Alexander disease observed in three siblings. This research contributes to the understanding of the disease's phenotypic spectrum.